Carl Zeiss Meditec to Acquire IanTECH, Inc. to expand its portfolio in cataract surgery
Jena/Germany | Carl Zeiss Meditec AG
ZEISS to enhance its portfolio of Surgical Ophthalmology solutions, further positioning the Company as a global innovation leader and solution provider in the full space of ophthalmology.
Carl Zeiss Meditec today announced it has entered into an agreement to acquire IanTECH. Headquartered in Reno, Nevada, IanTECH is a privately held company focused on technology solutions for micro-interventional cataract surgery.
Cataract surgery has been dependent on phaco technology for over 50 years. ZEISS believes that the market needs a fresh innovative approach in the field of phaco. IanTECH’s surgical technology is designed to change the future of managing cataracts. “We expect that IanTECH will complement our leading portfolio of equipment and consumables in cataract surgery, allowing us to offer physicians and patients a new standard of care,” says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec. “The technology has the potential to simplify challenging cases, reduce risk to patients and further improve outcomes while being easy to train and adapt for surgeons.”
“We are pleased to bring the IanTECH team and technology into the ZEISS family,” states James V. Mazzo, Global President Ophthalmic Devices at Carl Zeiss Meditec.
“We look forward to joining ZEISS to combine our efforts in bringing superior technology to the market and we are pleased to align with the great culture and commitment at ZEISS,” adds Brian Walsh, CEO of IanTECH.
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For more information visit our website at www.zeiss.com/med